menu search

SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
– PDUFA target action date for nirogacestat NDA in adults with desmoid tumors remains set for November 27, 2023 – – On track to report topline data from the Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN in the fourth quarter of 2023 – – Presented additional Phase 3 DeFi data at CTOS […] The post SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights appeared first on ForexTV... Read More
Posted: Nov 2 2023, 10:30
Author Name: forextv
Views: 112273

Search within

Pages Search Results: